Market News AIOpen the app

RPRX stock news · Royalty Pharma plc

Stories about Royalty Pharma plc (RPRX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for RPRX

Follow Royalty Pharma plc (RPRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RPRX
Free on the App Store and Google Play, or on the web.
  1. Sep 8, 2026, 10:31 AM ET · Market

    Eli Lilly's stock dropped on Tuesday. What's going on?

    Bad for RPRX

    Royalty Pharma is named as exposed to pelacarsen, and the failed trials are said to have weighed on its shares.

  2. Aug 13, 2026, 1:12 PM ET · Market

    $100M funding agreement secured by Royalty Pharma with Zealand Pharma for blood disorder treatment.

    Neutral

    Royalty Pharma has entered a $100 million funding agreement with Zealand Pharma for economic rights related to the blood disorder drug rusfertide. This strategic partnership is expected to enhance Royalty Pharma's revenue potential and support Zealand Pharma's drug development efforts, particularly as the FDA has set a goal date for rusfertide's New Drug Application in 2026.

  3. Aug 5, 2026, 7:39 AM ET · Market

    Royalty Pharma plc discloses operational results and financial status (RPRX).

    Neutral

    Royalty Pharma plc has filed a Form 8-K detailing its results of operations and financial condition, which is crucial for investors to assess the company's performance and future outlook. The immediate nature of this filing suggests it could lead to significant trading activity as investors react to the new information.